How has been the historical performance of Aarti Drugs?

Answer:The historical performance of Aarti Drugs shows a fluctuating trend in net sales and profits over the years, with net sales reaching 2,387.03 Cr in March 2025, down from 2,528.58 Cr in March 2024 and 2,716.05 Cr in March 2023. The total operating income followed a similar pattern, peaking at 2,716.05 Cr in March 2023 before declining to 2,387.03 Cr in March 2025. The operating profit (PBDIT) also experienced a decline, from 441.64 Cr in March 2021 to 303.43 Cr in March 2025. Profit before tax decreased from 369.01 Cr in March 2021 to 211.78 Cr in March 2025, while profit after tax showed a slight decrease from 280.40 Cr in March 2021 to 168.10 Cr in March 2025. The earnings per share (EPS) reflected this trend, with a decrease from 30.09 in March 2021 to 18.42 in March 2025. The operating profit margin and PAT margin also showed fluctuations, with the operating profit margin at 12.03% in March 2025 and the PAT margin at 7.04%.

Breakdown:
Aarti Drugs' financial performance over the years indicates a decline in net sales from 2,716.05 Cr in March 2023 to 2,387.03 Cr in March 2025, with total operating income following suit. The company's operating profit (PBDIT) decreased from a high of 441.64 Cr in March 2021 to 303.43 Cr in March 2025, reflecting challenges in maintaining profitability. Profit before tax also saw a downward trend, dropping from 369.01 Cr in March 2021 to 211.78 Cr in March 2025, while profit after tax remained relatively stable but lower than previous years, at 168.10 Cr in March 2025 compared to 280.40 Cr in March 2021. The earnings per share (EPS) decreased significantly from 30.09 in March 2021 to 18.42 in March 2025, indicating a reduction in shareholder returns. Overall, the operating profit margin and PAT margin exhibited variability, with the operating profit margin at 12.03% and the PAT margin at 7.04% in March 2025, suggesting a tightening of profit margins amidst fluctuating sales.